ArticleCancer discovery2017
Gut Microbes May Up PD-1 Inhibitor Response.
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Gut microbiota affects PD-L1 therapy and its mechanism in melanoma.Cancer immunology, immunotherapy : CII · 2025Review
- A bibliometric analysis of global research on microbial immune microenvironment in melanoma from 2012 to 2022.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Review
- Microbial dysbiosis and polyamine metabolism as predictive markers for early detection of pancreatic cancer.Carcinogenesis · 2020Article
- Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Frontiers in immunology · 2018Article
Corrections and comments
- Comment on
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Confirming the results of animal studies, new research shows that the composition of patients' microbiome influences their response to checkpoint inhibitors. Patients with melanoma who benefit from PD-1 inhibitors carry a greater variety of species and higher numbers of microbes in the
Indexed as
Identifiers
28336551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.